公开(公告)号：EP1259242B1

公开(公告)日：2007-08-15

申请号：EP01921298.4

申请日：2001-03-01

申请人： Novartis AG ,  The University of Melbourne ,  Southern Health ,  Atkins, Robert ,  Chadban, Steven James ,  Cooper, Mark Emmanuel ,  Gilbert, Richard Ernest ,  Hill, Prudence Ann ,  Kelly, Darren James ,  Nikolic-Paterson, David John ,  Novartis Pharma GmbH

发明人： ATKINS, Robert, Charles ,  CHADBAN, Steven, James ,  COOPER, Mark, Emmanuel ,  GILBERT, Richard, Ernest ,  HILL, Prudence, Ann ,  KELLY, Darren, James ,  NIKOLIC-PATERSON, David, John

IPC分类号： A61K31/505 ,  A61K31/506 ,  A61K31/00 ,  A61P13/12

CPC分类号： A61K31/5377 ,  A61K31/00 ,  A61K31/505 ,  A61K31/506

摘要： The present invention relates to the use of PDGF receptor tyrosine kinase inhibitors, especially of N-phenyl-2-pyrimidine-amine derivatives of formula (I), in which the symbols and substituents have the meaning as defined herein in free form or in pharmaceutically acceptable salt form, in the manufacture of a pharmaceutical composition for the treatment of diabetic nephropathy; to a method of treatment of warm-blooded animals, including humans, suffering from diabetic nephropathy; and to the use of a PDGF receptor tyrosine kinase inhibitor of the formula (I), wherein R1, is pyridyl bonded at a carbon atom, R2, R3, R5, R6 and R8 are each hydrogen, R4 is lower alkyl, R7 a radical of formula (II):-N(R9)-C(=X)-(Y)n-R10, wherein R9 is hydrogen, X is oxo, n is 0 and R10 is 4-methyl-piperazinyl-methyl, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating glomerulonephritis, chronic pyelonephritis or IgA nephropathy.

公开(公告)号：EP1348145B1

公开(公告)日：2006-09-27

申请号：EP01272674.1

申请日：2001-12-28

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： ZHANG, Xiaoxiao ,  YE, Ming ,  LI, Ruolin

IPC分类号： G02C7/00 ,  G02C7/06

CPC分类号： G02C7/06 ,  G02B5/32 ,  G02C7/00 ,  G02C7/043 ,  G02C7/044 ,  G02C2202/20 ,  G03H2270/55

摘要： The invention provides a multifocal optical lens having a holographic optical element that selectively redirects light to provide the wearer with a single image formed from a single focal power. The invention also provides a method for producing a multifocal optical lens having a holographic optical element.

公开(公告)号：EP0970114B1

公开(公告)日：2006-07-12

申请号：EP98924125.2

申请日：1998-04-16

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： DUTHALER, Rudolf ,  KATOPODIS, Andreas ,  KINZY, Willy ,  ÖHRLEIN, Reinhold ,  THOMA, Gebhard

IPC分类号： C07K14/00 ,  C07K1/107 ,  A61K47/48 ,  B01J20/26 ,  C07K16/06 ,  C07K1/22

CPC分类号： C07K14/001 ,  A61K38/00 ,  A61K47/645 ,  B01J20/26 ,  C07K1/1077 ,  C07K1/22 ,  C07K16/065

摘要： Polyamide conjugates comprising either (a) a xenoantigenic group; or (b) a biologically active group and a macromolecular, macro- or microscopic entity, bound to a polyamide backbone, processes for their preparation and the use of these conjugates in therapeutic compositions.

公开(公告)号：EP1309583B1

公开(公告)日：2006-06-21

申请号：EP01974118.0

申请日：2001-08-06

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： KINDER, Frederick, Ray

IPC分类号： C07D309/30 ,  C07C271/22 ,  C07F7/18

CPC分类号： C07F7/1852 ,  C07C259/06 ,  C07C271/12 ,  C07D309/30 ,  Y02P20/55

摘要： A more practical synthesis for preparing discodermolide and structurally related analogues, novel compounds useful in the process and novel compounds prepared by the process.

公开(公告)号：EP1352051B1

公开(公告)日：2006-06-07

申请号：EP01965205.6

申请日：2001-08-21

申请人： Novartis AG ,  Novartis Pharma GmbH ,  THE SCRIPPS RESEARCH INSTITUTE

发明人： YU, John

IPC分类号： C12N5/06 ,  A01K67/027 ,  A61P35/00

CPC分类号： A01K67/0271

摘要： The present invention provides a process for making an in vivo model of human leukemia. The process includes the steps of: pre-conditioning an immunodeficient rodent by administering to the rodent a sub-lethal dose of irradiation and injecting the rodent with an effective pre-conditioning amount of human fetal cord blood mononuclear cells; maintaining the rodent for from about 5 to 10 days; and injecting the rodent with an effective engrafting amount of primary human leukemia cells. An in vivo and in vitro model of human leukemia are also provided.

公开(公告)号：EP1332137B1

公开(公告)日：2006-03-29

申请号：EP01988712.4

申请日：2001-10-26

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： BUCHDUNGER, Elisabeth ,  CAPDEVILLE, Renaud ,  DEMETRI, George, Daniel ,  DIMITRIJEVIC, Sasa ,  DRUKER, Brian, J. ,  FLETCHER, Jonathan, A. ,  JOENSUU, Heikki, c/oHelsinki Univ Central Hospital ,  SILBERMAN, Sandra, Leta ,  TUVESON, David ,  HEINRICH, Michael, C.

IPC分类号： A61K31/506 ,  A61P35/00

CPC分类号： C07D401/04 ,  A61K31/506

摘要： 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of the formula (I) or a pharmaceutically acceptable salt thereof can be used in the treatment of gastrointestinal stromal tumours.

公开(公告)号：EP1220852B1

公开(公告)日：2006-01-18

申请号：EP00969490.2

申请日：2000-10-11

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： ALBERT, Rainer ,  EHRHARDT, Claus ,  HOMMEL, Ulrich ,  KALLEN, Jörg ,  MEINGASSNER, Josef, Gottfried ,  ROCHE, Didier ,  WATTANASIN, Sompong ,  WEITZ-SCHMIDT, Gabriele ,  WELZENBACH, Karl

IPC分类号： C07D401/06 ,  C07D243/08 ,  A61K31/4709 ,  A61K31/551

CPC分类号： C07K5/06139 ,  A61K38/05 ,  A61K31/00 ,  A61K2300/00

摘要： The invention provides novel diazepanes having interesting pharmaceutical properties, particularly in preventing or treating disorders or diseases mediated by LFA-1/ICAM-1, -ICAM-2 or -ICAM-3 interactions.

公开(公告)号：EP1273289B1

公开(公告)日：2005-11-23

申请号：EP02022257.6

申请日：1997-01-20

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： Tiemessen, Harry

IPC分类号： A61K9/107 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61K47/00 ,  A61K31/435

CPC分类号： A61K47/12 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/1075 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/436 ,  A61K47/10 ,  A61K47/24

公开(公告)号：EP1574502A1

公开(公告)日：2005-09-14

申请号：EP04005423.1

申请日：2004-03-08

申请人： Novartis AG

发明人： The designation of the inventor has not yet been filed

IPC分类号： C07D239/46 ,  C07D239/60 ,  C07D239/50

CPC分类号： C07D239/46 ,  C07D239/50 ,  C07D239/60

摘要： The invention relates to the use of compounds of the general formula
wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , X 1 and X 2 have the significances given in claim 1, and optionally the enantiomers and geometrical isomers thereof, for controlling parasites on warm-blooded animals.

摘要翻译： 本发明涉及通式的化合物的用途，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，R10，R11，R12，R13，X1和X2具有 权利要求1，以及任选的对映体和几何异构体，用于控制温血动物的寄生虫。

公开(公告)号：EP1563842A1

公开(公告)日：2005-08-17

申请号：EP04002296.4

申请日：2004-02-03

申请人： Novartis AG

发明人： The designation of the inventor has not yet been filed

IPC分类号： A61K35/78 ,  A61P1/00

CPC分类号： A61K36/185 ,  A61K36/42 ,  A61K2300/00

摘要： Described is the use of natural ingredients Simarouba amara dried bark or an extract thereof and low concentrations of Momordica charantia fruit extract either alone or in combination with each other in the resistance management and control of coccidiosis in poultry. It further relates to veterinary compositions containing said natural ingredients, the preparation of these veterinary compositions, a method of controlling coccidiosis in poultry comprising the administration of said natural ingredients or said veterinary compositions to poultry, and the use of said natural ingredients for the preparation of these veterinary compositions or for treating coccidial infections in poultry. The invention also comprises the use of said natural ingredients as an additive to dry or wet poultry food or drinking water for the prophylactic or curative treatment of coccidial infections in poultry.

摘要翻译： 描述了在家禽抗球虫病的抗性管理和控制中单独或组合使用天然成分Simarouba阿拉伯干燥的树皮或其提取物和低浓度的苦瓜果提取物。 它还涉及含有所述天然成分的兽用组合物，这些兽用组合物的制备，控制家禽中球虫病的方法，包括向家禽施用所述天然成分或兽药组合物，以及使用所述天然成分制备 这些兽用组合物或用于在家禽中治疗球虫感染。 本发明还包括使用所述天然成分作为干性或湿性家禽食品或饮用水的添加剂，以预防或治疗家禽中的球虫感染。